Therapeutic antibody discovery is time and cost-intensive. Here, the authors develop a machine learning-driven method enabling accelerated design of large and diverse single-chain variable fragments with high binding efficiency, especially at high levels of diversity.
- Lin Li
- Esther Gupta
- Matthew E. Walsh
